This site uses cookies to ensure the best viewing experience for our readers.
RedHill’s Clinical Trial Results Undermine Its Underwritten Offering

RedHill’s Clinical Trial Results Undermine Its Underwritten Offering

The gastro treatment company announced a successful Crohn's disease treatment trial two weeks ago. While investors initially seemed hyped, successful trials from competitors brought RedHill’s stock down since

Dror Reich | 10:22  12.08.2018

Nasdaq-listed RedHill Biopharma Ltd. announced an underwritten offering of $25 million on Thursday, pricing its American Depositary Shares (ADS) at $6 each, under its current trading price of $6.5.

For daily updates, subscribe to our newsletter by clicking here.


Founded in 2009, Tel Aviv-headquartered and listed RedHill develops orally-administered drugs mainly for gastrointestinal and inflammatory diseases. The company raised $40 million in 2015 by offering its ADS at $16.25 per unit, and $38 million in 2016 at $10.25 per unit. In mid-July, the company filed a preliminary shelf prospectus with the U.S. Securities and Exchange Commission, looking to raise $116.9 million.

Nasdaq. Photo: Nasdaq Nasdaq. Photo: Nasdaq Nasdaq. Photo: Nasdaq

Two weeks ago, RedHill published successful results for its phase III clinical trial for the treatment of Crohn's Disease, a chronic, inflammatory disease of the digestive tract. While the company’s stock initially jumped by over 30% on Nasdaq during pre-market trading, reaching as high as $10.75, successful results from competing trials saw RedHill close the day in the red and continue to slide since.

Related stories

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., is the sole book-running manager for the offering, which is expected to close on August 14. RedHill intends to use the proceeds for clinical development.

share on facebook share on twitter share on linkedin share on whatsapp share on mail